[3H]-salbutamol added in tracer doses (~ 250 nmol per animal) to the carrier solution (20 mg/kg) was injected intraperitoneally to pregnant rats on the 19th day of gestation. Some experiments were performed with intravenous administration (~ 2.5 µCi in 300 µl 9 g/1 NaCl). Drug distribution was studied in the maternal and fetal plasma, lung and liver, and in the placenta and amniotic fluid. 10% of the maternal salbutamol plasma radioactivity was recovered in the fetal plasma, in accordance with earlier findings reported from our laboratory using human placental lobules in vitro.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.